{"messages":[{"status":"ok","category":"all"}], "collection":[{"title":"Incidence of Symptoms Associated with Post-Acute Sequelae of SARS-CoV-2 infectionin Non-Hospitalized Vaccinated Patients Receiving Nirmatrelvir-Ritonavir","authors":"PATEL, R.; Dani, S. S.; Khadke, S.; Ahmad, J.; Shah, J.; Mehta, N.; Wener, K.; McQuillen, D. P.; Abraham, G.; Faust, J.; Maley, J.; Patel, S.; Mullington, J.; Wachter, R.; Mosenthal, A.; Sax, P.; Ganatra, S.","author_corresponding":"Sarju Ganatra","author_corresponding_institution":"Lahey Hospital and Medical Center","doi":"10.1101\/2023.04.05.23288196","date":"2023-04-06","version":"1","type":"PUBLISHAHEADOFPRINT","license":"cc_no","category":"infectious diseases","jatsxml":"https:\/\/www.medrxiv.org\/content\/early\/2023\/04\/06\/2023.04.05.23288196.source.xml","abstract":"BackgroundThe role of Nirmatrelvir plus ritonavir (NMV-r) in preventing post-acute sequelae of SARS-CoV-2 infection (PASC) is unknown. The objective of this study is to assess the effect of NMV-r in non-hospitalized, vaccinated patients on the occurrence of PASC.\n\nMethodsWe performed a comparative retrospective cohort study utilizing data from the TriNetX research network, including vaccinated patients [&ge;]18 years old who subsequently developed Covid-19 between December 2021-April 2022. Cohorts were based on NMV-r administration within five days of diagnosis. Based on previously validated broad and narrow definitions, the main outcome was the presence of symptoms associated with PASC. Outcomes were assessed between 30-180 days and 90-180 days after the index Covid-19 infection.\n\nResults1,004 patients remained in each cohort after propensity-score matching. PASC (broad definition) occurred in 425 patients (42%) in the NMV-r cohort, vs. 480 patients (48%) in the control cohort (OR 0.8 CI 0.67-0.96; p=0.01) from 30-180 days and in 273 patients (27%) in the NMV-r cohort, as compared to 347 patients (35%) in the control cohort (OR 0.707, CI 0.59-0.86; p<0.001) from 90-180 days. Narrowly defined PASC was reported in 337 (34%) patients in the NMV-r and 404 (40%) in the control cohort between 30-180 days (OR=0.75, CI 0.62-0.9, p=0.002) and in 221 (22%) in the NMV-r cohort as compared to in 278 (28%) patients in the control cohort (OR=0.7, CI 0.63-0.9, p=0.003) between 90 -180 days.\n\nConclusionsNMV-r treatment in non-hospitalized vaccinated patients with Covid-19 was associated with a reduction in the development of symptoms commonly observed with PASC and healthcare utilization.\n\nKey PointsAssessment of Nirmatrelvir plus ritonavir (NMV-r) in preventing post-acute sequelae of SARS-CoV-2 infection (PASC), based on broad and narrow definitions in non-hospitalized, vaccinated patients between 30-180 days and 90-180 days.","published":"NA","server":"medRxiv"}]}